In tissue engineering and regenerative medicine, a biomaterial provides mechanical support and biochemical signals to encourage cell attachment and modulate cell behaviour. Nature’s template for a biomaterial is the extracellular matrix (ECM). The ECM contains intrinsic biochemical and mechanical cues that regulate cell phenotype and function in development, in homeostasis and in response to injury.
ECM Therapeutics, Inc. ("ECMT") has obtained worldwide exclusive rights from the University of Pittsburgh for an extensive patent portfolio in certain fields of use based upon Extracellular Matrix ("ECM") technologies developed in the laboratory of Dr. Stephen Badylak at the McGowan Institute for Regenerative Medicine, and collaboratively with other Pitt investigators. The licensed technology includes ECM hydrogels, bioactive derivatives of ECM, and other forms of ECM, as well as methods required to deliver these materials to various anatomic sites such as the central nervous system, portions of the gastrointestinal tract, and musculoskeletal system, among others.